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Abstract
Although the influence of context-dependent endothelial cell regulation of vascular disease and
repair is well-established, the privileged roles endothelial cells play as paracrine regulators of
tumor progression has only recently become appreciated. We hypothesized that if the same
endothelial physiology governs vascular and cancer biology then endothelial cell control in cancer
should follow endothelial regulation of vascular health. Healthy endothelial cells promote vascular
repair and inhibit tumor invasiveness and metastasis; dysfunctional endothelial cells have the
opposite effects. We now ask if dysfunctionally activated endothelial cells will promote cancer
cell inflammatory signaling and aggressive properties. Indeed, while factors released from
quiescent ECs induce balanced inflammatory signaling, correlating with decreased proliferation
and invasiveness, factors released from dysfunctional ECs robustly activated NF-κB and STAT3
signaling within cancer cells, correlating with increased in vitro invasiveness and decreased
proliferation and survival. Furthermore, matrix-embedded dysfunctional endothelial cells
stimulated intratumoral pro-inflammatory signaling and spontaneous metastasis, while
simultaneously slowing net primary tumor growth, when implanted adjacent to Lewis lung
carcinoma tumors. These studies may broaden our realization of the roles of endothelial function
and dysfunction, increase understanding and control of the tumor microenvironment, and facilitate
optimization of anti-angiogenic and vascular-modifying therapies in cancer and related diseases.
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Introduction
Endothelial cells (ECs) control vascular repair, and vascular health is defined by endothelial
integrity.1 Healthy or “quiescent” ECs promote vascular repair, limiting EC injury restricts
vascular disease, and vascular healing is enhanced when EC injury is contained2 or when
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injured endogenous ECs are replaced by exogenous EC implants.3 The contranegative is true
as well – diseased or “dysfunctional” ECs exacerbate vascular injury. Such EC paracrine
regulatory control should not be restricted to the macrovasculature as ECs are part of every
tissue, lining not only the luminal surface of large vessels but also the perfusing
microvasculature of every organ. Indeed, ECs also regulate the repair of organs much as
they do arteries.4
The acknowledged roles of ECs in tumor biology continue to evolve. Endothelial disarray,
as part of vascular structural abnormalities, contributes to abnormal intra-tumoral perfusion
and a vicious cycle of local hypoxia, impaired permeability, extracellular matrix degradation
and efflux of cancer cells.5 That healthy ECs also limit cancer cell proliferation and invasion
through biochemical regulation analogous to vascular healing adds an element to this
continuum.6 Questions arise whether regulation is restricted to the control imposed by
healthy ECs and whether paracrine interactions induce dysfunctional ECs to promote, not
simply permit, disease progression. We hypothesize that “dysfunctional” (i.e. inflamed and
otherwise pathologically activated) ECs stimulate cancer aggressiveness like they promote
vascular disease, not only from loss of regulatory ECs but from the stimulation of pathologic
processes by dysfunctional ECs.7 Moreover, we propose that the pro-inflammatory and
hyper-activated intratumoral milieu modulates EC paracrine secretion, transforming the EC
phenotype from quiescent and disease-inhibitory to dysfunctionally activated and disease-
stimulatory.
We examined the response of cancer cells in culture and in murine tumors to pathologically
deranged “dysfunctional” ECs (DECs) using a model system inspired by both vascular and
tumor biology paradigms. Although important factors like biomechanical stress8, hypoxia9,
and presence of other stroma10 are not directly modeled herein, DECs share many
phenotypic features with dysfunctional ECs from the atherosclerosis milieu11, 12 and ECs
harvested directly from tumors.13 Our studies should help to expand the “angiocrine” tumor-
regulatory paradigms, expand analogies between EC paracrine regulatory mechanisms in the
fields of non-malignant vascular disease and tumor biology, and aid in the design of more
effective therapies that target or utilize endothelial cells in a range of disease states.
Materials and Methods
Reagents
Antibodies to NF-κB p65 and p-p65, integrin β3, VE-cadherin, p-TIE2, p-STAT3, cleaved
PARP, fibrillarin, GAPDH, β-actin, and α-tubulin were from Cell Signaling Technology.
The CD11b antibody was from Abcam. Antibodies to perlecan, VE-cadherin, VEGFR2, and
NF-κB p65 (immunofluorescence) and HRP-conjugated secondary antibodies were from
Santa Cruz Biotechnology. The antibody to eNOS was from Abcam. Fluorescently-labeled
secondary antibodies and calcein-AM were from Invitrogen. Recombinant human TNF-α
was from BioLegend; VEGF and FGF2 were from Invitrogen. BAY 11-7082 was from
Cayman Chemicals.
Cell culture
A549, NCI-H520, HOP62, and HOP92 lung carcinoma cells and THP-1 (monocytic
leukemia) cells (ATCC) were cultured in RPMI with 10% FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin. Human umbilical vein ECs (HUVECs, Invitrogen) were cultured
in EGM-2 (Lonza) with 5% FBS on gelatin-coated plates, passages 3–6. EC-conditioned
media were generated from confluent HUVEC monolayers by 48 hours of culture in
MCDB131 (Invitrogen) with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin;
cell morphologic phenotype was stable during the conditioning period. Cells and debris were
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removed by centrifugation (5 minutes, 500g) and media aliquotted and stored at −80°C.
Conditioned medium (48 hr, 6 mL EGM-2 per 10-cm dish) pooled from the four cancer cell
lines grown to confluence replaced 33% of the volume of EGM-2. 10 ng/mL TNF-α, 10 ng/
mL VEGF, and 1 ng/mL FGF-2 was added to comprise the “dysfunctional” EC (DEC)
growth medium - a modification of a published protocol used to generate surrogate “tumor-
associated” ECs in culture.13
Matrix-embedded ECs (MEECs) were generated by culturing ECs within sterile Gelfoam
compressed matrices (Pfizer, New York).4 ECs were seeded onto hydrated 1.25×1×0.3 cm
blocks and allowed to attach for 1.5 hours before seeding the contralateral side. Two blocks
were added to 30-mL polypropylene tubes and cultured for up to 3 weeks. Samples from
each lot were digested with collagenase (type I, Worthington Biochemicals) and seeding
efficiency determined with a Z1 particle counter (Beckman Coulter). Cell viability was
assessed by trypan blue exclusion.
In vitro cell number, proliferation, apoptosis, tube-forming, permeability, monocyte
adhesion, and invasion/migration assays
Cell number—Cells were detached with trypsin and counted with a Z1 Coulter particle
counter (Beckman Coulter). Alternatively, the reduction of MTS reagent (Promega) was
monitored per the manufacturer’s instructions.
Proliferation—Incorporation of BrdU was monitored via BrdU ELISA (Cell Signaling
Technology) per the manufacturer’s instructions.
Apoptosis—Caspase-3/7 activity was examined using the ApoONE kit (Promega) per the
manufacturer’s instructions.
Tube forming—15,000 ECs were seeded in each well of 96-well plate coated with 50 μL
of Matrigel (BD Biosciences). After 16–20 hours, tube/cord formation was imaged by phase
contrast microscopy and tube length in the central low-power field quantified by ImageJ.
Monolayer permeability—ECs were seeded onto transwell inserts (0.4 μm pores, BD
Biosciences) and grown to post-confluence in 4 days. Then the medium in the upper
chamber was changed to EGM-2 plus 0.1 mg/mL FITC-dextran (70 kD, Sigma), and
medium in the lower chamber was changed to fresh EGM-2. Diffusion was allowed to occur
for 1 hour at 37°C, after which the inserts were removed and an aliquot was taken from the
lower chamber for quantification with a Varioskan Flash instrument (Thermo), with
concentration calculated from a standard curve. Results were normalized per EC in the
control condition.
Monocyte adhesion—ECs were seeded onto gelatin-coated 24-well plates and grown to
post-confluence over 4 days. 5×105 calcein AM-labeled THP-1 cells in 100 μL of RPMI
were seeded onto the monolayers and allowed to adhere for one hour at 37°C. Nonadherent
cells were removed by gentle washing with PBS, and monolayers were lysed in 0.1% SDS
and lysates were transferred to an optically neutral 96-well plate. Fluorescent signal was
measured with a Varioskan Flash plate reader (Thermo), with background from EC
monolayers without THP-1 cells subtracted from all measurements and results normalized
per EC in the control condition.
Invasion/migration—Chemoinvasion kits (BioCoat, BD) were used per the
manufacturer’s instructions. Invaded or migrated cells adherent to the bottom of the inserts
were fixed, stained with DAPI (1 μg/mL, 30 minutes) and imaged by epifluorescence
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microscopy. Images were analyzed by visual inspection and cytometric quantification of 4
random 20X fields at the microscope or by using the “particle counter” feature of ImageJ for
the central 10X field. Data are expressed as an invasion index14, the average number of
invaded cells and the average number of migrated cells of a given condition, normalized to
the control condition with at least 3 wells used per condition.
Gene expression analysis
Total RNA was purified (RNEasy Mini Plus, Qiagen) and cDNA synthesized (TaqMan
reverse transcription reagents, Applied Biosystems) using 1 μg of RNA per sample. Real-
time PCR analysis was performed (Opticon II instrument, MJ Research) using SYBR Green
PCR Master Mix (Applied Biosystems) and appropriate primers (Table 1). Gene expression
was quantified using the ΔΔCt method, with 18SRNA or GAPDH as a housekeeping gene.
qPCR primer arrays (Lonza) were used for medium-throughput gene expression analysis.
Protein expression analysis
Whole cell extracts were harvested in 0.5% Triton X-100, 0.1% SDS, protease inhibitor
cocktail (Roche), 2 mM sodium orthovanadate, 50 mM sodium fluoride, and 4 mM PMSF.
Nuclear and cytoplasmic protein fractions were obtained as described elsewhere.15 Samples
were separated on glycine-SDS gels, transferred to nitrocellulose membranes,
immunoblotted with the appropriate primary and HRP-conjugated secondary antibodies, and
detected with a chemiluminescent peroxidase substrate (Luminata Forte, Millipore) for
luminescence detection with a FluorChem luminometer (Alpha Innotech; CA) and analysis
with ImageJ. A cytokine antibody array (RayBiotech; GA) was used per the manufacturer’s
instructions for assessment of cell biosecretions. Array luminescence was imaged using a
FluorChem luminometer and quantified with ImageJ. Quantification of individual secreted
factors present in cell supernatants was via ELISA (RnD Systems; MN) per the
manufacturer’s specifications.
For immunofluorescence imaging, cells were fixed in paraformaldehyde and stained with
primary antibodies and AlexaFluor 594-conjugated secondary antibodies (Invitrogen);
nuclei were counterstained with DAPI. Images were acquired with a Nikon microscope and
analyzed using either ImageJ (NIH) or CellProfiler (Broad Institute).
Murine tumor model
All animal experiments were approved by the MIT Committee on Animal Care in
compliance with NIH guidelines. Female C57BL6 mice, ~6 weeks of age (Jackson
Laboratories) were used in the Lewis lung carcinoma (LLC) implantation-resection-
metastasis model, in which early metastases are suppressed by angiostatin elaborated from
the primary tumor; hence removal of the primary tumor allows macroscopic growth of lung
metastases.16 Lewis lung carcinoma cells (ATCC) were passaged serially through mice for
two generations before use to bolster metastatic capacity, then 106 LLC cells were injected
in the subcutaneous dorsum. After 6 days for tumor engraftment, acellular matrix (control),
MEECs (~1E6 cells per animal), or dysfunctional MEECS (D-MEECs, ~1E6 cells per
animal) were implanted adjacent to tumors, which were ~30 mm3 in volume. After 8
additional days, tumors and implants were excised. 14 days after the resection, the animals
were sacrificed by CO2 inhalation. 2% isoflurane anesthesia was administered via nose cone
and 0.1 mg/kg buprenorphine administered perioperatively. Tumor dimensions were
measured with Vernier calipers, using two orthogonal measurements to estimate volume
assuming prolate spheroid geometry.
Franses et al. Page 4
Int J Cancer. Author manuscript; available in PMC 2014 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Statistical analysis
Experiments were performed at least thrice for validation and each time in triplicate, at
minimum. Results are expressed as mean ± SEM. Comparison of two groups was performed
using a student’s t-test. Comparison of >2 groups was performed using ANOVA followed
by t-tests. p<0.05 was taken as statistically significant.
Results
Dysfunctionally activated endothelial cells (DECs) have dysregulated phenotypes
Our “DECs” were stimulated with a combination of factors mimicking various aspects of the
tumor microenvironment (cancer-secreted factors, angiogenic factors, and a pro-
inflammatory cytokine). The DECs were generated using a modification of a protocol used
to create surrogate tumor ECs, which have similar gene expression profiles to ECs harvested
directly from tumors.13 DECs grew more slowly in culture, with 42±2% fewer cells at
confluence than control “quiescent” (meaning healthy, not referring to proliferative rate in
culture) ECs (p=0.002, Fig. 1A), and were larger with a mesenchymal morphology, unlike
the cobblestone appearance of quiescent postconfluent ECs (Fig. 2B). Relative to ECs,
DECs formed tubes less efficiently on Matrigel (26±9% reduction, p=0.007, Fig. 1B), had
dramatically increased permeability (2.5±0.4-fold p=0.036, Fig. 1C), and higher avidity for
binding THP-1 monocytes (4.4±0.3-fold, p=3.5*10−7, Fig 1D). Indices of endothelial
activation were increased and of quiescence reduced (Fig 2A). DECs possessed, relative to
control ECs, increased phosphorylation of VEGFR2 (8.7±2.6 fold increase, p=0.022) and
total integrin β3 (2.3±0.4 fold increase, p=0.023), and decreased VE-cadherin (39±12%
decrease, p=0.04), and phosphorylated Tie2 (81±7% decrease, p=0.009). eNOS protein
expression was also downregulated in DECs (92±1% decrease, p=8.5*10−6), although
possible compensatory increases in eNOS activity were not examined in this work. Further,
localization of signaling proteins changed, with a 67±12% decrease in surface-localized and
cytoplasmic VEGFR2 and an 84±6% decrease in VE-cadherin in DECs relative to ECs (p <
0.05 for each, Fig. S2).
DECs showed a 10-fold increase in the percentage of cells with NF-κB p65 nuclear
localization after 4 days of culture (p=0.005, Fig. 2B), suggesting a sustained pro-
inflammatory state. These results were verified by examination of the nuclear and
cytoplasmic protein fractions from ECs and DECs (Fig. S1): DEC nuclei contained ~3.5
times more NF-κB p65 and STAT3β than EC nuclei. Additionally, DECs showed very low
expression of intact perlecan (Fig. 2B), a molecule important for maintaining the quiescent
EC phenotype.6, 17
The gene expression profile of DECs is pro-inflammatory and pro-thrombotic
As ECs adopt a mesenchymal morphology in association with endothelial-to-mesenchymal
transition (EndMT) and may play a role in inflammatory and tumor-associated states18, 19
we examined gene expression changes of EndMT-associated transcription factors in DECs.
There were ~3-fold increases in the levels of Snail and Twist transcripts (each p<0.05, Fig.
S3) and widespread changes in the DEC transcriptome relative to that of EC controls (Fig.
2C). The expression of many pro-inflammatory NF-κB target genes – e.g. GM-CSF, IL-8,
IL-6, and E-selectin – were significantly increased, the expression of quiescence-promoting,
anti-inflammatory genes – e.g. eNOS, VE-cadherin, Ang1 – were decreased, the expression
of leukocyte adhesion molecules VCAM1 and ICAM1 were increased, and the balance of
coagulation-related genes shifted toward a pro-coagulant state (higher tissue factor, TF, and
lower thrombomodulin, THBD). Analysis of protein secretion by cytokine blots (Fig. 2D) of
ECs and DECs corroborated and extended the identified gene expression changes: DECs
secreted much higher amounts of pro-inflammatory cytokines MCP-1, IL-6, IL-8, GRO-α/
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CXCL1, RANTES, G-CSF, MCP-2, GM-CSF, and MCP-3. Importantly, although the
culture cocktail used to generate “DECs” contained 10 ng/mL TNF-α, this protein was
undetectable in DEC-conditioned media, indicating that exogenous TNF-α was removed by
washing before conditioned media collection. It is likely that the other EC-activating factors
were similarly removed before conditioning.
We analyzed the expression of selected genes in ECs treated for four days with the
individual (cancer cell secretions, TNF-α, VEGF, FGF2) components of the DEC cocktail to
discriminate their specific effects on EC gene expression (Fig. S4A). Replacement of 33%
of the culture medium with media from cancer cells had similar effects to TNF-α (10 ng/
mL) alone, and when combined with TNF-α recapitulated most of the effect of the complete
cocktail. However, as evidenced for example by eNOS gene expression, the complete
cocktail was more effective in altering EC gene expression profiles than individual
components. EC gene expression profile was not dramatically changed by sustained culture
in saturating concentrations of VEGF and FGF2, implying a resistance by postconfluent ECs
to pro-angiogenic activation.
Cancer cell proliferation, apoptosis, inflammation, and invasiveness
Quiescent ECs inhibit the proliferation and invasiveness of cancer cells, much like they
control vascular smooth muscle hyperplasia and monocyte recruitment, in a manner that
correlates with steady-state inhibition of pro-inflammatory signaling and is reversed with
targeted disruption of the healthy EC phenotype.6 Since the DEC phenotype was highly
deranged and pro-inflammatory, we hypothesized that DECs would be cancer-stimulatory
along multiple axes.
The net growth of three different cancer lines was significantly inhibited by EC media,
(p<0.003, Fig. 3A), and even further by DEC media (~80% reduction, p<3*10−7 for all
versus control; p<0.04 for all versus EC media). Inhibition of cancer growth correlated with
a ~20% reduction in BrdU incorporation for both EC- and DEC-conditioned media (p<0.05
versus control for all cancer cell lines, Fig. 3B). DECs, unlike ECs, robustly induced
apoptosis as detected by an assay for caspase-3/7 activity (3.4±0.4-fold versus control for
A549, 1.7±0.1-fold for NCI-H520, and 2.4±0.2-fold for HOP62 relative to control). These
results were verified further in A549 cells by Western blot analysis of cleaved and total
PARP (p=0.013 versus control, p=0.033 versus EC, Fig. 3C). Although the DEC secretome
contains ~5-fold more IL-6, than the EC secretome (Fig. 2D), and IL-6 can itself induce
cancer cell apoptosis20, the enhanced stimulation of cancer cell apoptosis by DEC medium
was not inhibited by neutralization of IL-6 activity (Fig S5).
Pro-inflammatory signaling in cancer cells has been implicated in many facets of the
disease15, 21, and though cytokines such as IL-6 can kill cancer cells, those that survive tend
to be particularly aggressive and metastatic.20 Therefore we examined signaling through the
STAT3 and NF-κB pathways in A549 lung carcinoma cells after variable time in EC or
DEC-conditioned media culture (Fig. 4A). DECs increased STAT3 phosphorylation at 24
hours 6.2±0.8-fold (p=0.0006), which inverted to a 79±3% decrease (p=0.0002) by 96 hours.
Secretions from quiescent ECs in contrast only minimally activated STAT3 in A549 cells at
24 hours (1.7±0.3-fold, p=0.049) that inverted to a 46±14% (p=0.037) decrease by 96 hours.
Similarly, there was a 1.7±0.1-fold increase (p=0.035) in NF-κB p-P65 induced by DEC-
conditioned media at 4 hours that increased to 5.0±0.8 fold by 24 hours (p=0.0046) and
remained elevated at 96 hours (p=0.01). Here too EC media induced a smaller pro-
inflammatory response, with a trend toward (p=0.075) increased p-P65 at 24-hrs and
moderate sustained activation at 96 hours (p=0.0055). Intriguingly, the observed changes in
NF-κB activation caused by EC media were associated with a 1.6±0.4-fold increase
(p=0.047) in IκBα at 24 hours, supporting the notion of a controlled, balanced activation of
Franses et al. Page 6
Int J Cancer. Author manuscript; available in PMC 2014 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
cancer cell inflammatory pathways by EC secretions. We examined a subset of the p-STAT3
and p-P65 Western blots for A549 cells NCI-H520 and HOP62 cells (Fig. S7), and the
additional results agreed with our findings in A549 cells (Fig. S7). In all experiments we
normalized phosphoprotein Western blot data with either tubulin or actin, rather than to the
total quantities of the signaling proteins, since the concentrations of these species were
constant over a time period of days.
Intense stimulation of pro-inflammatory signaling in A549 cells by DEC media might
stimulate invasive properties, an in vitro correlate of metastasis. As in prior studies6 media
from quiescent ECs inhibited in vitro invasiveness of A549 cells by 33±10% (p<0.005, Fig.
4B), but DECs stimulated A549 invasiveness by 39±18% (p<0.01, Fig. 4B). These effects
correlated directly (r2 = 0.93, Fig. 4D) with a 32±7% decrease in A549 nuclear NF-κB
immunofluorescent staining by culture in EC media (p=0.037, Fig. 4C) and a 2.1±0.4-fold
increase by DEC media (p=0.022, Fig. 4C). Indeed, inhibition of NF-κB nuclear
translocation with an irreversible inhibitor of IkBa phosphorylation22 reversed the ability of
DEC media to stimulate A549 invasiveness (Fig. S6).
Together, our results suggest a controlled, sustained anti-proliferative and anti-invasive
effect on cancer cells by quiescent ECs and a pro-inflammatory, invasion-stimulatory effect
on cancer cells by dysfunctional ECs.
Adjacent D-MEECs stimulate spontaneous metastasis
We used the Lewis lung carcinoma implantation-resection-metastasis model to examine EC-
cancer in vivo regulation (Fig. S8). Although a heterotopic xenograft, the model allows for
facile surgical access and robust spontaneous metastasis.16 We generated matrix-embedded
quiescent ECs (MEECs) or dysfunctional ECs (D-MEECs) by prolonged culture in the same
cocktail used to create in vitro DECs. We have previously showed that use of such
implantable endothelial constructs allows sustained implant viability and does not engender
a host immunological rejection.23 The D-MEEC phenotype was altered relative to MEEC
phenotype in a manner similar to DECs versus ECs (Fig. S9).
D-MEEC implants had significant effects on the behavior of adjacent tumors. Tumor
volumes were equal (~30 mm3) at MEEC/D-MEEC implantation. Adjacent D-MEEC
implants reduced tumor volumes 14 days post-implant by 54±14% relative to controls
(p=0.048, Fig. 5A). Reduction in size correlated with a 68±10% reduction in Ki67 labeling
index (p=0.02, Fig. 5B) and a 67±13% increase in the number of cleaved caspase-3 events
per 10X field (p=0.0001, Fig. 5C). In concert with defined effects of quiescent EC implants,
MEECs induced a 39±9% lower Ki67 index than control implants (p=0.006, Fig. 5B) but no
gross effects on Lewis lung tumor growth or metastasis.
Inflammatory markers were also affected by adjacent endothelial implants. Concomitant
with reduction in primary tumor size by D-MEECs, there was a 16±5% increase (p=0.011,
Fig. 5D) in the fraction of nuclei within tumor cryosections that stained for NF-κB p65. This
increase in inflammatory signaling correlated with increase in the metastatic properties of
the D-MEEC treated Lewis lung primary tumors. Four of five animals in this group had
macroscopic lung metastatic nodules involving all lung lobes, and the same animals each
had regional cervical metastatic tumors (p<0.05 each by proportion z-test). Only one of five
animals in the acellular control matrix group exhibited regional recurrence and
macroscopically identifiable lung nodules. Although there was a 23±4% reduction
(p=0.0002, Fig. 5D) in inflammatory signaling within MEEC-treated primary tumors, there
was no reduction in metastasis relative to the control group in these animals. Differences in
tumor behavior induced by adjacent MEEC or D-MEEC implants could not be explained by
macrophage recruitment (Fig. S10). Thus, adjacent D-MEEC implants directly affected the
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egress of blood-borne, metastatic cancer cells most likely via elaboration of pro-
inflammatory factors such as those identified in vitro.
These results support our in vitro results and demonstrate that biochemically “dysfunctional”
EC implants can retard tumor growth but enable metastasis, presumably from stimulation of
pro-inflammatory signaling pathways in the cancer cells.
Discussion
ECs line every vessel, sensing and biochemically responding to flow from above, strain and
stress from below and local density at their periphery. These vantage points allow regulation
of multiple aspects of local biology. The dynamic response of the EC secretome to
microenvironmental perturbations allows the EC to provide a range of paracrine effects.
This capability, entrenched in our understanding of vascular disease, has re-emerged in
tumor biology.24 We recently demonstrated paracrine regulatory effects of ECs in cancer.
Quiescent ECs – similar to those that inhibit vascular smooth muscle hyperplasia and
thrombosis after vascular injury25, 26 – inhibited in vitro cancer proliferation and
invasiveness, and in vivo tumor growth and metastasis6.
We now show that dysfunctionally activated ECs can robustly promote the pro-
inflammatory signaling within and hence the invasiveness of cancer cells. The isolated
phenotype of our in vitro “dysfunctional” ECs is similar to the dysfunctional ECs of
macrovascular disease7 and tumor-derived ECs.13 Activated integrin (e.g. integrin β3) and
extracellular matrix expression27, dysregulated leukocyte adhesion (e.g. by altering
expression of E-selectin, VCAM-1, etc.)28, abnormal responses to oxidative stress29, and
abnormal response to the mechanical microenvironment30 likely arise from pathologically
activating stimuli common to both the tumor21, 31, 32 and atherosclerotic milieux.33, 34 Thus,
the paracrine effects of dysfunctional ECs are useful in examining cell-cell crosstalk in
cancer, atherosclerosis, and other diseases, with the caveat that no in vitro model can fully
recapitulate the complex anatomy and physiology of any tissue.
Continued examination of paracrine effects of dysfunctional ECs adds to work investigating
the contribution of inflammatory signaling to tumor progression.31, 32 The NF-κB15 and
STAT321 signaling pathways are particularly important in controlling cancer-stimulatory
pro-inflammatory signals relevant for tumor growth and metastasis. Activation of these
pathways profoundly affects cancer cells and tumor stroma.35 We observed activation of the
inflammatory pathways in a stromal cell (the EC) inducing NF-κB activation in cancer cells,
leading to increased cancer invasion and metastasis. Recently, Pitroda et al demonstrated
that tumor endothelial inflammatory signatures correlate with prognosis.36
Further, the dynamics of inflammatory signaling may be particularly important in cancer-
stroma crosstalk interactions. NF-κB-induced transcriptional changes are context-
dependent37 and rely on the relative quantities of interacting proteins like IκBα.38 We
observed that while quiescent ECs induced moderate activation of
inflammatory pathways within target cancer cells and inhibited the proliferation and
invasion of cancer cells, dysfunctional ECs induced more profound pro-inflammatory
signaling during all time points examined. DECs stimulated cancer cell apoptosis, but the
surviving cancer cells were very aggressive. Quiescent ECs may not be strictly anti-
inflammatory, but rather might induce controlled inflammation, with balanced action of
activating (e.g. NF-κB P65) and inhibiting (IκBα) components, to direct wound healing and
cancer inhibition. Thus, just as in vascular disease and repair, ECs are capable of inhibiting
tumor aggressiveness, but this inhibitory phenotype can be changed to a tumor stimulatory
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phenotype. Future work should delineate more fully the differential NF-κB and STAT3
signaling dynamics induced within cancer cells by ECs of a range of phenotypes.
We have used matrix-embedded EC (MEEC) constructs to investigate paracrine regulatory
processes in a wide range of injury3, 4, 39 and tumor models.6 A relatively small number (~1
million) of implanted matrix-embedded ECs modulate local tissue physiology without
extravasation/invasion of the implanted cells into the host or immune rejection of the
implants – testimony to the paracrine potency of ECs23. In prior work, quiescent MEEC
implants guided repair, limited morphological and immunohistochemical markers of
malignancy and of metastatic potential, and restrained cancer progression.6 Here,
dysfunctional EC constructs stimulated pro-inflammatory signaling within adjacent tumors
and significantly increased spontaneous metastasis. These findings are in line with the
notion of a cancer-inhibitory physiologic microenvironment40 that is eventually co-opted by
tumors and are a direct extension of the context-dependent regulatory effects in vascular
disease, wherein quiescent ECs suppress and dysfunctional endothelial cells stimulate
diverse disease processes.
The use of intact cells rather than isolated molecules offers the opportunity to affect cancer
biology broadly, but also poses a challenge in defining specific mechanism(s). It is
appealing to search for a single molecule or pathway to define a cellular effect. Indeed, we
previously showed that controlled disruption of the endothelial phenotype – via silencing of
the gene encoding perlecan, a heparan sulfate proteoglycan critical for endothelial inhibition
of thrombosis after vascular injury17 – eliminated EC ability to inhibit cancer invasion and
metastasis. EC secretion of IL-6, which is known to stimulate metastasis20, 41, increases
when the quiescent phenotype is disrupted and with perlecan silencing.6 Yet, the IL-6
upregulation can also be seen with general stress and chemotherapy42 and neutralization of
IL-6 activity in DEC medium had no effect on induction of apoptosis in cancer cells.
Paracrine regulatory effects are determined by the coordinated activity of the cell secretome,
and many canonical signaling pathways are densely interconnected.32 In contrast to dosing
with isolated biologic factors, intact cells release a spectrum of regulatory molecules in a
dynamic manner and in temporally and physiologically relevant proportions. The EC and
DEC effects on cancer and vascular biology likely represent synergistic effects.43
Thus, these studies may implicate dysfunctional stromal ECs as active contributors to the
tumor microenvironment and explain how anti-angiogenic therapies that damage the
vasculature may shrink tumors and add months to patient survival44 but under some
circumstances stimulate cancer invasion and metastasis.45, 46 The perceived role of ECs in
cancer is expanding from the structural lining of tumor-perfusing blood vessels to a stromal
paracrine regulatory element.24, 47–50 Future work will help define how the tumor
microenvironment can make endogenous tumor-associated endothelium dysfunctional and
what specific endothelial-derived products may dominate particular cancer-regulatory
phenomena. Such studies may illustrate deeper similarities between the tumor endothelial
phenotype and the dysfunctional endothelial phenotype observed in diverse diseases
including atherosclerosis, hypertension, and diabetes. They may also implicate previously-
unforeseen consequences stemming from therapies that target the tumor vasculature.
Lessons learned may motivate the development of novel pharmacologic or cell-based
interventions – or the redirecting of therapies that regulate endothelial health – to slow or
reverse tumor progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty, impact
This work describes how dysfunctionally activated and inflamed endothelial cells can
stimulate cancer aggression, just as similarly activated endothelial cells stimulate
atherogenesis. This work adds to known roles of endothelial cells in cancer while
showing how insights into non-malignant vascular biology may guide future work in the
vascular biology of cancer.
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Figure 1. The in vitro “dysfunctional” EC (DEC) phenotype includes dysregulated proliferation,
tube formation, high permeability, and avid monocyte binding
(A) Growth curve of endothelial cells cultured under intact (“EC”) or dysfunctional
(“DEC”) in vitro conditions. (B) Tube length per field of ECs and DECs after 2 days of
culture. (C) Permeability to the passage of FITC-dextran of confluent EC or DEC
monolayers after 4 days of culture. (D) Adhesion of THP-1 monocytic leukemia cells to
confluent EC or DEC monolayers after 4 days of culture. * p<0.05 versus EC by t test. n = 4
per condition.
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Figure 2. The DEC phenotype manifests in increased dysfunctional indices, reduced quiescent
indices, altered and inflamed morphology, and highly pro-inflammatory and pro-thrombotic
expression profiles
(A) Western blot of whole cell lysates of ECs and DECs, with quantification for DEC
lysates relative to EC lysates. (B) Immunofluorescent staining for actin (fluorescent
phalloidin), perlecan, and NF-κB p65 in ECs and DECs. Nuclei are labeled in blue (DAPI).
(C) qRT-PCR array analysis of endothelial inflammatory, thrombotic, and quiescent
differentiation genes. (D) Cytokine dot blot of EC and DEC secretions. * p<0.05 by t test. n
= 3 per condition.
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Figure 3. ECs inhibit cancer cell proliferation, but pro-inflammatory DECs induce cancer cell
death
(A) MTT assay of the A549, NCI-H520, and HOP62 lung carcinoma cells after 4 days of
culture in either unconditioned (control), EC-conditioned, or DEC-conditioned media. (B)
BrdU incorporation of the same cells during hours 24–48 of culture in the same sets of
conditioned media. (C) Caspase-3/7 activity in A549, NCI-H520, and HOP62 cells, and
Western blot of full and cleaved PARP in A549 cells, after 4 hours of culture. * p<0.05
versus control, + p<0.05 versus EC by t test. n = 3 per condition.
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Figure 4. ECs control lung cancer inflammatory signaling and reduce invasiveness, whereas
DECs robustly stimulate lung cancer inflammatory signaling and stimulate invasiveness
(A) Time course of STAT3 (p-STAT3) and NF-κB pathway activity (p-P65 and IκBα)
induced by unconditioned (control), EC-conditioned, or DEC-conditioned media as assayed
by Western blot of whole cell lysates of A549 cells. Quantification, relative to control, is
shown above each representative band. (B) In vitro chemoinvasion index of A549 cells after
4 days of culture in the same sets of conditioned media. (C) Immunofluorescent nuclear
localization of NF-κB p65 in A549 cells after 4 days of culture in the same sets of
conditioned media. (D) Correlation between effects of EC or DEC secretions on A549
invasiveness and NF-κB p65 nuclear localization. * p<0.05 versus control, + p<0.05 versus
EC by t test. n = 3 per condition.
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Figure 5. Adjacent D-MEECs cause increased spontaneous metastases and in parallel slow the
net growth of primary tumors
(A) Tumor volumes estimated by caliper measurements of explanted Lewis lung carcinoma
tumors. (B) Percent of Ki67-positive nuclei of thresholded immunofluorescent primary
tumor cryosection images. (C) Numbers of host (murine) cleaved caspase 3 events per 10X
field of immunofluorescent primary tumor cryosections. (D) Percent of NF-κB p65-positive
nuclei of immunofluorescent primary tumor cryosections. (E) Table showing fractions of
mice with macroscopic regional (posterior cervical) metastasis and with pan-lobar
macroscopic lung metastases 2 weeks after primary tumor resection. * p<0.05 versus control
by t test. + p<0.05 versus MEEC by t test. ^ p<0.05 by proportion z-test. n = 6 per condition.
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Table 1
Primer sequences for qRT-PCR gene expression analysis.
Gene Forward Primer (5′-3′) Reverse Primer (5′-3′)
GAPDH ACAGTCAGCCGCATCTTCTT TGGAAGATGGTGATGGGATT
Twist1 ATCAAACTGGCCTGCAAAAC TGCATTTTACCATGGGTCCT
Snail CTAGAGTCTGAGATGCCCCG GTTCTGGGAGACACATCGGT
Slug CTTTTTCTTGCCCTCACTGC GCTTCGGAGTGAAGAAATGC
Sip1 ATTGGTTTTCCTCCCTTGCT AAGCAGGAACCCTCTCATCA
IL-6 CACAAGCGCCTTCGGTCCAGTT TCTGCCAGTGCCTCTTTGCTGC
THBD ACTGTGACTCCGGCAAGGTGGA AAAAGCGCCACCACCAGGCA
eNOS TTGCTCGTGCCGTGGACACA TGGCGCTTCCAGCTCCGTTT
E-selectin AACCCCGAGCGAGGCTACATGA ACACAGTGCCAAACACGGGCTC
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